Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Blend Innovative Growth & Defense With Healthcare ETFs

BY | ETF Database
5:21 am ET 09/11/26 | 9 VIEWS
  • Related Symbols
  • XLV
All too often, when investors look at the healthcare sector, they mostly see its value for its defensive merits. However, that view may be shortsighted and miss the broader picture in today’s market.Key Takeaways: Traditionally speaking, investors look to gain targeted healthcare exposure as a means of portfolio defense. Today, healthcare companies offer compelling long-term growth through innovative developments like GLP-1 sales, AI, surgical robotics, precision oncology, and more. The State Street Health Care Select Sector SPDR ETF (XLV) offers low-cost access to health care companies, with the added benefit of a potent track record. Recent insights from the team at State Street Investment Management examined the opportunity set within the healthcare sector. The report indicated that while healthcare still has defensive potency, it is also seeing more long-term growth opportunities due to innovation within the sector. Innovation in the healthcare field is happening on multiple fronts. State Street noted that GLP-1 sales are continuing to grow and are expected to hit $190 billion by 2035. Meanwhile, AI adoption is proving to be highly useful in the drug development process for pharmaceutical companies. See More: Apple’s Foldable iPhone Duo Steals the Spotlight The innovation isn’t stopping there, either. Gene therapies, precision oncology, surgical robotics, and many other tools are reshaping the growth opportunities within the healthcare sector.Healthcare Innovation Comes Alongside Traditional DefenseOf course, this is all playing out while healthcare companies offer significant defensive advantages. Demand for healthcare is fairly inelastic, even amid inflation and rising prices. After all, when folks are sick, spending money on medicine and hospital treatments is often not really an option. “The next growth cycle is unlikely to mirror the previous one, but healthcare remains one of the few sectors capable of combining defensive characteristics with innovation-led growth, making it a valuable source of diversification within equity portfolios — and one with a growing innovation tilt that may offer the potential for a more competitive performance profile,” State Street said in the report. See More: Tap Into Defense & Long-Term Opportunities With Utilities Putting this all together, the mix of long-term growth and defensive stability makes the healthcare sector one worth considering tilting into in today’s landscape. As macroeconomic risks persist, healthcare stocks can protect against inflation while tackling long-term growth through innovation. This opportunity set can bode well for the State Street Health Care Select Sector SPDR ETF (XLV A). XLV offers access to the healthcare companies within the S&P 500. Many of these companies, such as Eli Lilly (LLY), are among those that are best-positioned to benefit from growth in the healthcare sector. The fund’s recent track record may also add to the case for leaning into healthcare. As of August 31, 2026, XLV’s NAV has risen 26.20%, year to date. For more news, information, and analysis, visit our Sector Investing Content Hub.

More Commentary

Why Rare Earths are Becoming a New Defense Priority
BY | ETF Database
6:15 am ET 09/11/26 | 10 VIEWS
XLC: Combining AI Growth & Telecom Defense
BY | ETF Database
8:34 am ET 09/11/26 | 4 VIEWS
Japan Rotation Supports Case for This ETF
BY | ETF Database
7:38 am ET 09/11/26 | 5 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.